What is the maximum dose of Entresto (sacubitril/valsartan) per administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Dose of Entresto Per Administration

The maximum dose of Entresto per administration is 97 mg sacubitril/103 mg valsartan taken twice daily, which represents the target dose for adults with heart failure with reduced ejection fraction (HFrEF). 1

Dosing Details

Standard Adult Dosing

  • Target/Maximum dose: 97 mg sacubitril/103 mg valsartan twice daily
  • Starting dose: 49 mg sacubitril/51 mg valsartan twice daily (or 24 mg/26 mg twice daily in certain circumstances)
  • Titration: Double the dose every 2-4 weeks as tolerated to reach the target dose 1

Special Populations Requiring Dose Adjustment

Patients requiring half the starting dose (24 mg/26 mg twice daily initially):

  • Severe renal impairment (eGFR <30 mL/min/1.73 m²)
  • Moderate hepatic impairment (Child-Pugh B)
  • These patients can still be titrated toward the maximum dose of 97/103 mg twice daily as tolerated 2

Contraindicated populations:

  • Severe hepatic impairment (Child-Pugh C) - no studies conducted, not recommended 2

Clinical Context and Evidence

Importance of Target Dose Achievement

The 2022 AHA/ACC/HFSA guidelines emphasize that titration to target doses shown efficacious in randomized controlled trials is recommended (Class 1, Level A evidence) to reduce cardiovascular mortality and heart failure hospitalizations 1. However, real-world data shows achieving target doses can be challenging:

  • In clinical practice, only 27% of patients achieved the 200 mg (97/103 mg) twice daily dose within 6 months 3
  • Main barriers include hypotension (25%), slower uptitration protocols (55%), and patient noncompliance 3

Dose-Response Relationship

Research demonstrates clear dose-dependent benefits:

  • Mortality and hospitalization: The 97/103 mg dose showed significantly lower all-cause mortality (9.27%) compared to 49/51 mg (17.58%) and 24/26 mg (29.63%) doses 4
  • Heart failure hospitalization: Rates were 16.10% with 97/103 mg versus 29.14% with 24/26 mg (HR 1.79,95% CI 1.18-2.73) 4
  • NT-proBNP reduction: Benefits were consistent across all dose levels, though higher doses trended toward greater reductions 5

Key Clinical Pitfalls

Common dosing errors to avoid:

  • Premature dose acceptance: Don't settle for lower doses without attempting uptitration; the mortality benefit is dose-dependent 4
  • Excessive caution with blood pressure: Symptomatic hypotension occurred in only 1.35-fold higher rates versus control, and efficacy was maintained across dose levels 6
  • Overlooking titration windows: Guidelines suggest titration as frequently as every 1-2 weeks is reasonable, not the slower protocols often used in practice 1

Safety considerations at maximum dose:

  • Hypotension is the most likely adverse effect from overdosage 2
  • In healthy volunteers, doses up to 583 mg sacubitril/617 mg valsartan (single dose) and 437 mg/463 mg (14 days) were well tolerated 2
  • The drug is unlikely to be removed by hemodialysis due to high protein binding 2

Practical Uptitration Algorithm

  1. Start: 49/51 mg twice daily (or 24/26 mg if severe renal/moderate hepatic impairment)
  2. Week 2-4: Double to 97/103 mg twice daily if SBP >100 mmHg and no symptomatic hypotension
  3. Monitor: Blood pressure, renal function, potassium (especially if on MRA - 10% hyperkalemia risk) 7
  4. Maintain: 97/103 mg twice daily as the therapeutic target dose

The evidence strongly supports aggressive uptitration to the maximum dose of 97/103 mg twice daily whenever tolerated, as this provides the greatest mortality and morbidity benefit in HFrEF patients 1, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.